Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[3]  Bingshu E. Chen,et al.  Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience , 2020, Breast Cancer Research and Treatment.

[4]  R. Greil,et al.  Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial , 2019, Cancer.

[5]  M. Ceppi,et al.  Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial , 2019, International journal of cancer.

[6]  R. Greil,et al.  Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial. , 2019, Journal of Clinical Oncology.

[7]  Bingshu E. Chen,et al.  Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials , 2019, The Lancet.

[8]  A. Gavin,et al.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.

[9]  T. Fehm,et al.  German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Laing,et al.  Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial , 2017, The Lancet. Oncology.

[11]  David Cameron,et al.  11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial , 2017, The Lancet.

[12]  J. Cuzick.  Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  E. Perez,et al.  Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Barni,et al.  Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial , 2015, The Lancet.

[15]  S. Barni,et al.  Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials , 2015, Breast Cancer Research and Treatment.

[16]  M. Dimopoulos,et al.  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial , 2014, BMC Cancer.

[17]  Ling Chen,et al.  Second malignancies after breast cancer : The impact of adjuvant therapy ( Review ) , 2022 .

[18]  S. Paik,et al.  Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Hall,et al.  Risk of ischemic heart disease in women after radiotherapy for breast cancer. , 2013, The New England journal of medicine.

[20]  Yuanyuan Zhang,et al.  Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. , 2012, Breast.

[21]  M. Dimopoulos,et al.  Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial , 2012, Breast Cancer Research and Treatment.

[22]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.

[23]  N. Magné,et al.  Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials , 2012, Breast Cancer Research and Treatment.

[24]  L. Leibovici,et al.  Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials , 2010, Journal of the National Cancer Institute.

[25]  U. Dafni,et al.  Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. Reiss,et al.  Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer , 2007, Breast Cancer Research and Treatment.

[27]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Holmes,et al.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Norton,et al.  The Norton–Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens , 2006, Nature Clinical Practice Oncology.

[30]  P. Bruzzi,et al.  Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. , 2005, Journal of the National Cancer Institute.

[31]  U. Dafni,et al.  Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Ahluwalia,et al.  Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.

[34]  B. Overmoyer,et al.  Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Bruzzi,et al.  HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients , 2005, British Journal of Cancer.

[36]  J. Bryant,et al.  Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[38]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  L. Norton,et al.  Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  G. Bonadonna,et al.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.

[42]  J. Willem,et al.  Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.

[43]  G. Bonadonna,et al.  Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Anna L. Brown,et al.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Levine,et al.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  N Harbeck,et al.  Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.